Abstract
Although the aetiology of MS remains elusive, several genetic approaches have provided clues to the underlying molecular pathogensis. In addition to the well known association to HLA class II alleles, weak but highly significant association to the interleukin-7 receptor and interleukin-2 receptor genes has recently been established. A series of other promising candidate genes identified in large genome screens are under evaluation. The genetic predisposition to MS is so far shown to be mediated by common polymorphisms in genes encoding molecules involved in T cell activation and homeostasis, but only a small proportion of the potential susceptibility genes have yet been identified. Analyses of transcribed immune receptor genes have revealed evidence of antigen-driven clonal expansion of lymphocytes, and may also provide tools for charting their specificites. Recently, attempts to identify disease-associated genes through transcriptional profiling have revealed new candidate players in MS pathogenesis. Whereas genetic studies in humans may identifiy individual molecular players, transgenic animal models allow detailed examination of molecular pathways. These studies have shown that in addition to altered protein function, alteration of gene expression may contribute to disease development. We here review how different genetic approaches can be combined to elucidate the immunopathogenesis of MS.
Current Molecular Medicine
Title: Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Volume: 9 Issue: 5
Author(s): Trygve Holmoy, Hanne Harbo, Frode Vartdal and Anne Spurkland
Affiliation:
Abstract: Although the aetiology of MS remains elusive, several genetic approaches have provided clues to the underlying molecular pathogensis. In addition to the well known association to HLA class II alleles, weak but highly significant association to the interleukin-7 receptor and interleukin-2 receptor genes has recently been established. A series of other promising candidate genes identified in large genome screens are under evaluation. The genetic predisposition to MS is so far shown to be mediated by common polymorphisms in genes encoding molecules involved in T cell activation and homeostasis, but only a small proportion of the potential susceptibility genes have yet been identified. Analyses of transcribed immune receptor genes have revealed evidence of antigen-driven clonal expansion of lymphocytes, and may also provide tools for charting their specificites. Recently, attempts to identify disease-associated genes through transcriptional profiling have revealed new candidate players in MS pathogenesis. Whereas genetic studies in humans may identifiy individual molecular players, transgenic animal models allow detailed examination of molecular pathways. These studies have shown that in addition to altered protein function, alteration of gene expression may contribute to disease development. We here review how different genetic approaches can be combined to elucidate the immunopathogenesis of MS.
Export Options
About this article
Cite this article as:
Holmoy Trygve, Harbo Hanne, Vartdal Frode and Spurkland Anne, Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update, Current Molecular Medicine 2009; 9 (5) . https://dx.doi.org/10.2174/156652409788488793
DOI https://dx.doi.org/10.2174/156652409788488793 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Drug Encapsulated Nanoparticles for Treating Targeted Cells
Current Medicinal Chemistry Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer
Current Drug Metabolism DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Current Medicinal Chemistry Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Meet Our Executive Editor
Current Traditional Medicine Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine